Nexavar
| Covered Uses: | All FDA approved indications not otherwise excluded from Part D. Additional coverage for off-label uses in the treatment of gastrointestinal stromal tumors and metastatic thyroid cancer is provided. |
| Exclusion Criteria: | Combination use with other tyrosine kinase inhibitors such as sorafenib, sunitinib |
| Required Medical Information: | For GIST - coverage is provided after disease progression with imatinib and sunitinib |
| Age Restrictions: | |
| Prescriber Restrictions: | |
| Coverage Duration: | 12 months |
| Other Criteria: |
Last Modified on 12/19/2012